Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 30 n° 328

Posts Tagged ‘healthcare’

Hologic to Webcast Presentation at the 30th Annual Piper Jaffray Healthcare

Posted by fidest press agency su lunedì, 19 novembre 2018

Conference Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 30th Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 28 at 8 a.m. Eastern Time. The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcast will be available for 30 days following the event.Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit http://www.hologic.com

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Intersect ENT to Present at the Piper Jaffray 30th Annual Healthcare Conference

Posted by fidest press agency su venerdì, 9 novembre 2018

Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will participate in the 30th Annual Piper Jaffray Health Care Conference on November 28 at the Lotte New York Palace in New York City, and will present in a session at 10:30am ET.
A replay of the session will be available via the investors section of the company’s website at http://www.intersectENT.com. The webcast replay will be archived for approximately one month.
Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients. The company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Kala Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference

Posted by fidest press agency su venerdì, 9 novembre 2018

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Jefferies 2018 London Healthcare Conference in London, U.K.. Todd Bazemore, Chief Operating Officer at Kala Pharmaceuticals, will provide a corporate overview on Wednesday, November 14, 2018 at 2:00 PM GMT.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYSTM (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

IQVIA to Present at the Credit Suisse Annual Healthcare Conference on November 13, 2018

Posted by fidest press agency su giovedì, 8 novembre 2018

IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), announced today that Michael McDonnell, executive vice president and chief financial officer, will speak at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 1:40 p.m. MST / 3:40 p.m. EST.A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast also will be available later that day.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps its customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit http://www.iqvia.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Exelixis to Present at the Stifel 2018 Healthcare Conference on November 13, 2018

Posted by fidest press agency su giovedì, 8 novembre 2018

Exelixis, Inc. (NASDAQ: EXEL) announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the Stifel 2018 Healthcare Conference taking place November 13-14 in New York, NY. The Exelixis presentation is scheduled for 10:15 AM EST / 7:15 AM PST on Tuesday, November 13, 2018.
To access the webcast link, log onto http://www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our three commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib), and have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Cerus to Present at the Baird 2018 Global Healthcare Conference

Posted by fidest press agency su lunedì, 3 settembre 2018

Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ vice president, finance and chief financial officer, will present and provide a corporate update at the Baird 2018 Global Healthcare Conference in New York City on Thursday, September 6, 2018 at 8:30 a.m. ET.A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Infolock Kicks Off 3rd Annual Healthcare IT Security Leaders’ Summit

Posted by fidest press agency su domenica, 26 agosto 2018

Today, leading data advisory consulting firm Infolock kicked off its third annual Healthcare IT Security Leaders’ Summit at its corporate headquarters outside Washington, DC. The two-day, invite-only conference brings together IT and information security executives and industry experts and covers topics including blockchain applications for the healthcare industry, HIPAA enforcement, the future of AI in clinical settings, GDPR regulatory compliance and data privacy, managing privilege attacks, user-entity behavioral analytics, and other topics.When asked about the event, Ryan Dobbins, director of advisory services for Infolock said, “It’s a remarkable and unique experience for us to host the Summit, and we routinely hear from our attendees that it’s the best conference or meeting they attend all year long. That’s incredibly gratifying for us. We’re laser focused on avoiding vendor marketing in the subject matter presented — something we feel ruins other similar events — and it clearly shows in the quality and vigor of the dialogue we spark between and among participants. We think the industry needs more probing, challenging conversations and fewer long-form commercials.” Speakers from the U.S. Department of Health and Human Services’ Office of Civil Rights, Community Health Systems, The Center for Internet Security, the Virginia Modeling, Analysis, and Simulation Center at Old Dominion University, Polsinelli, BeyondTrust, Bay Dynamics, and Infolock will present over the course of two days. Attendees include executives from Penn Medicine, Sentara Healthcare, Temple University Health System, Orthofix, Gateway Health, Augusta Health, Valley Health, and others. In response to a question about previous years’ events and their most valuable insights, attendee Michael Bray, senior director of information security and compliance at Community Health Systems in Franklin, TN said, “Having the opportunity to hear directly from HHS OCR regarding breach reporting and enforcement, and getting the legal community’s perspective on effective breach response, was invaluable.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference

Posted by fidest press agency su domenica, 5 agosto 2018

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 2:30 pm ET at the Parker New York, in New York City, NY. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is being evaluated in combination with other agents in multiple tumor types in a Phase 1/1b program, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and will be tested in combination with Arcus’s other product candidates. Arcus’s other programs include an anti-TIGIT antibody AB154, which is in a phase 1 program, and a small molecule inhibitor of CD73 AB680, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit http://www.arcusbio.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

NextGen Healthcare to Present at Upcoming Investor Conferences

Posted by fidest press agency su venerdì, 25 maggio 2018

Quality Systems, Inc. (NASDAQ: QSII), known to its clients as NextGen Healthcare, announced today that President and Chief Executive Officer, Rusty Frantz, and Chief Financial Officer, Jamie Arnold will present at upcoming investor conferences.
Mr. Frantz and Mr. Arnold are scheduled to present at the Jefferies Global Healthcare Conference in New York City on Tuesday, June 5, 2018, at 4:00 PM EDT.
Mr. Frantz and Mr. Arnold are also scheduled to present at the William Blair and Company 38th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 12, 2018 at 1:30pm CDT.
Live audio-only webcasts and related presentation materials will be available on the investor relations section of the Company’s website at investor.qsii.com.Quality Systems, Inc., known to its clients as NextGen Healthcare, provides a range of software, services, and analytics solutions to medical and dental group practices. The company’s portfolio delivers foundational capabilities to empower physician success, enrich the patient care experience, and enable the transition to value-based healthcare. Visit http://www.qsii.com and http://www.nextgen.com for additional information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018

Posted by fidest press agency su sabato, 12 maggio 2018

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2018 on Thursday, May 17, 2018 at 10:00 AM Pacific Time. The conference will be held at the Encore Hotel in Las Vegas, Nevada.
A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at http://www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK. Please visit http://www.clovisoncology.com for more information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Aerpio Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

Posted by fidest press agency su venerdì, 23 marzo 2018

Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 3:00 p.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company’s lead compound, AKB‐9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. http://www.aerpio.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018

Posted by fidest press agency su venerdì, 23 marzo 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 17th Annual Needham Healthcare Conference on March 27th, 2018, at 3:30 p.m. ET at the Westin Grand Central Hotel in New York, New York.You can access the live webcast of the presentation via the “Investors & Media” section of our website, http://www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.
ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s proprietary pipeline includes: Derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA; Miransertib (ARQ 092), a selective inhibitor of the AKT serine/threonine kinase, in a phase 1/2 company sponsored study for Overgrowth Diseases, in a phase 1 study for ultra-rare Proteus syndrome conducted by the National Institutes of Health (NIH), as well as in multiple oncology indications; ARQ 751, a next generation AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. In addition, we have advanced ARQ 531, an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic options. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds. You can follow us on Twitter and LinkedIn.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

PAVmed to Present at the 28th Annual Oppenheimer Healthcare Conference

Posted by fidest press agency su venerdì, 16 marzo 2018

PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the 28th Annual Oppenheimer Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m. Eastern time. Dr. Aklog will provide a corporate overview, discuss the Company’s innovative business model and review PAVmed’s lead products. The conference will be held March 20-21, 2018 at the Westin New York Grand Central in New York City.Dr. Aklog’s presentation will be webcast live and available for replay in the Events and Presentations section of the Company’s website at ir.pavm.com/events-presentations.
PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its three lead products provide groundbreaking approaches to carpal tunnel syndrome (CarpX™), vascular access (PortIO™) and pediatric ear infections (DisappEAR™). The company is also developing innovative products in other areas, such as medical infusions and tissue ablation, while seeking to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For further information, please visit http://www.pavmed.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Award-Winning Healthcare System Installs Carestream’s Clinical Collaboration Platform to Enhance Its Image Management Workflow

Posted by fidest press agency su giovedì, 8 febbraio 2018

CARESTREAMDickinson County Healthcare System (Iron Mountain, Mich.) — a recipient of multiple healthcare quality awards — implemented Carestream Health’s Clinical Collaboration Platform (see video link) that features enterprise imaging, vendor-neutral archiving and Vue Motion enterprise viewer module. The Dickinson County system includes a community hospital and five satellite clinics.
“After evaluating several different PACS systems we selected Carestream because its fully featured platform is easy to use and offers the ability to read all modalities from a single workstation,” said Sherry Koepp, the healthcare system’s Manager of Imaging Services.The hospital’s Clinical Collaboration Platform supports lesion management, 3D tools, breast tomography, cardiac CT, breast MR and post processing. It also allows radiologists to read multiple modalities from a single workstation. The radiologists’ reading worklist is color coded so they can easily prioritize STAT reads over high priority or routine exams.Carestream’s advanced features are part of a unified platform that includes vendor-neutral archiving (VNA). “Our original plan was to purchase a separate VNA but our Carestream healthcare IT specialist recommended that we expand our storage area network with Carestream’s VNA software. This significantly reduces our cost without any sacrifice in performance or security,” Ms. Koepp explains.Both radiologists and physicians benefit from the platform’s critical results notification capabilities. “Radiologists can contact physicians to discuss critical results and answer any questions, which is an important factor in optimizing patient care,” reports David Alexa, the healthcare system’s PACS Administrator. The hospital also implemented Carestream’s Vue Motion enterprise viewer, which offers convenient access to patients’ images, videos, waveforms and reports from FDA-approved mobile devices.“Our referring physicians appreciate the ability to view the report and key images on mobile devices. Our ENT, orthopaedic, pulmonary and other specialists use the viewer to aid in diagnosis and treatment for patients,” said Mr. Alexa.System administrators use Carestream’s Vue Beyond to improve departmental workflow. This platform provides real-time monitoring of metrics that include study volume, modality mix, patient type and report turnaround time.Carestream’s Clinical Collaboration Platform delivers standards-based data capture, management, archiving and distribution for imaging data across the healthcare enterprise. The platform’s unified core is the backbone that enables enterprise imaging and associates all data for each patient with a single patient record. This imaging data can be easily integrated within a healthcare facility’s EMR/EHR. (photo: CARESTREAM)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Healthcare, Poverty, and Education are Closely Linked – How Do We Move Forward?

Posted by fidest press agency su venerdì, 19 gennaio 2018

london-centralLondon. According to Dr. Charles (Chuck) Basch, author of Healthier Students Are Better Learners, health issues, which disproportionately plague low-income urban minority youth, play a major role in limiting students motivation and ability to learn.It is estimated that 800 million people are spending at least 10 percent of their household budget on out-of-pocket health care expenses, and nearly 100 million people are being pushed into extreme poverty each year due to health care costs. The United Nations Sustainable Development Goal 3 aims to achieve Universal Healthcare for all people by 2030.According to Kara Hanson, Professor of Health System Economics at the London School of Hygiene & Tropical Medicine, there are two main challenges for healthcare in low and middle-income countries. The first challenge is the “growing burden of non-communicable diseases.” Hansen says that “more than half of the disease burden in lower-middle income countries is due to non-communicable diseases, and even in the lowest income countries, non-communicable diseases are responsible for one-third of the disease burden.”The Millennial Bloggers can be found all around the world. They are innovators and are dedicated to education; their merit can be seen throughout their efforts to educate and lead.“There are so many challenges confronting humanity that we need to be deploying capital differently,” says Bonnie Chiu who argues that “impact investing is the key to funding universal access to healthcare.” A Columbia University study found that in 2008, the average doctor in the US earned $186,582, while in Canada, a country with higher healthcare satisfaction, the average doctor earns $125,000. “Broadening taxation and reducing spending would be ideal ways to balance the books,” says Jacob Navarette. “A truly modern health system needs to focus on enabling choice within itself,” notes James Kernochan.The Millennial Bloggers are Alusine Barrie, Sajia Darwish, James Kernochan, Kamna Kathuria, Jacob Deleon Navarrete, Reetta Heiskanen, Shay Wright, Isadora Baum, Wilson Carter III, Francisco Hernandez, Erin Farley, Dominique Alyssa Dryding, Harry Glass, Harmony Siganporia and Bonnie Chiu.CMRubinWorld launched in 2010 to explore what kind of education would prepare students to succeed in a rapidly changing globalized world. Its award-winning series, The Global Search for Education, is a celebrated trailblazer in the renaissance of the 21st century, and occupies a special place in the pulse of key issues facing every nation and the collective future of all children. It connects today’s top thought leaders with a diverse global audience of parents, students and educators. Its highly readable platform allows for discourse concerning our highest ideals and the sustainable solutions we must engineer to achieve them. C. M. Rubin has produced over 600 interviews and articles discussing an expansive array of topics under a singular vision: when it comes to the future of children, there is always more work to be done.

Posted in Estero/world news, scuola/school | Contrassegnato da tag: , , | Leave a Comment »

QuintilesIMS is now IQVIA

Posted by fidest press agency su mercoledì, 8 novembre 2017

new yorkNew York. QuintilesIMS (NYSE:Q) today announced that it will be changing its name to IQVIA, a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients, effective November 6, 2017. Beginning on November 15, 2017, equity shares of the company will trade on the NYSE under the new name and new ticker symbol “IQV.” Until then, IQVIA will continue to be listed under QuintilesIMS and symbol “Q” per the listing notification requirements of the NYSE.
IQVIA’s client solutions are powered by the IQVIA CORE™. The CORE enables IQVIA to provide customized solutions for clients leveraging the world’s largest curated healthcare information source, advanced analytics, leading technologies and extensive industry knowledge across diseases, geographies and scientific methods. It fuels the company’s approach to human data science, including faster, more predictable clinical development, innovative approaches to generating real-world evidence, machine learning to improve patient care, and strategies for precision commercial engagement. The seamless integration of these elements from molecule to market enables our customers to drive enhanced value, access and health outcomes around the world.“Today is a defining moment for our organization as we introduce a new name that aligns with our vision to help stakeholders drive healthcare forward,” said IQVIA Chairman and CEO Ari Bousbib. “Our clients have been instrumental in our becoming IQVIA. IMS Health and Quintiles came together because our clients were asking for better, faster ways to bring innovations to patients and capture the improvements the industry has been pursuing for years. Since the merger, we’ve worked to integrate our capabilities in advanced analytics, leading technologies and therapeutic expertise into powerful, differentiated offerings. Our vision is to outpace the inevitable progress of change across the life sciences and accelerate our ability to empower healthcare decision makers to meet the future head on.”IQVIA’s ongoing commitment to data security and privacy protection measures and decades of deep, practical experience are critical drivers of our global leadership. As a company, we will continue to engage in a wide variety of governance practices and administrative, technical and physical safeguards and controls to protect individual privacy. We work closely with data protection authorities, trusted third parties and privacy experts around the world to ensure we are diligent in the protection of individual privacy.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Growth Opportunity Assessment of Healthcare IT Market in France – Forecast to 2021 – Research and Markets

Posted by fidest press agency su martedì, 31 ottobre 2017

borsaUK, Germany, France and Spain collectively spend more than $6 billion on healthcare information technology (healthcare IT) while regional adoption stands at almost 80%. Healthcare IT markets in these countries are ready to embark upon the next level of digitalisation where providers move from data capturing solutions to those that can derive value from data through improving information sharing, analytics and clinical decision support. France embarked upon the Digital Hospital Strategy as part of its five-year plan (from 2012 to 2017) with the goal of fully digitizing the care delivery system by the end of this period. In spite of a high level of EMR adoption, the country suffers from delays and cost over-runs in comparison to the initial digitalisation plans and intends to rapidly progress towards Stage 5-7 EMRs over the next three years. Integrating care delivery is a key priority for the health system as a whole, which includes developing facets like remote health monitoring, telemedicine, mHealth and IoMT, which enable care delivery outside the hospital. The research found that only a little more than 15% of large hospitals across EU share data beyond their organization. This has been a huge detriment to efficient and productive health data utilization across all countries included in this study. However, with changing care paradigms, such as focus on patient-centricity, innovation in care delivery models, and demand for workflow efficiency, improving health data continuity will be a key goal for both governments and providers over the next five years. As a result, interoperability, and standards development and adoption will be major priorities across health systems.France is also targeting improving collaboration and data sharing between healthcare providers and care settings, especially to enable remote care for the elderly and the chronically ill. Inconsistent implementation of initiatives, such as the Dossier Medical Patient (DMP), for establishment of HCIT infrastructure has resulted in fragmented adoption and created complex data silos. To achieve the goal of improving population health, France will need a more harmonized approach to healthcare digitalisation. The eHealth Strategy 2020 has resulted in a business environment conducive to the growth of eHealth vendors. Business models that demonstrate positive clinical and financial outcomes along with partnerships with key stakeholders will be the key to success.Consumers are playing an increasingly evident role in managing their own health. More than 20% of patients in France use connected devices with a high propensity for using them for chronic disease management. France also showcases an unusually high affinity amongst physicians to advocate use of connected devices to support home monitoring. As a result, telehealth technologies and remote care delivery models will emerge as a key growth opportunity and the government is already working towards establishing a regulatory framework that makes sustainable business models through reimbursements possible in this arena.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Maratona di 24 ore completamente dedicata all’healthcare

Posted by fidest press agency su venerdì, 4 novembre 2016

merckRoma. Merck, azienda leader in ambito scientifico e tecnologico, annuncia che, il 5 e 6 novembre prossimi, si terrà a Roma, all’interno di Talent Garden di Cinecittà, (Via V. Lamaro, 30), H-ACK MERCK FOR HEALTH: una maratona di 24 ore completamente dedicata all’healthcare.Nel corso dell’evento, centinaia di ragazzi, provenienti da tutta Italia e non solo, si uniranno in team per sviluppare soluzioni innovative per il settore rispondendo ai brief lanciati dall’azienda.H-ACK MERCK FOR HEALTH, organizzato da Merck in partnership con H-FARM, è l’evento conclusivo di un progetto di open innovation iniziato lo scorso aprile e mirato a favorire l’utilizzo e la nascita di nuove applicazioni digitali a sostegno dei settori della sanità e della salute.“La diffusione del digitale in ambito Healthcare sta radicalmente modificando gli scenari del settore, aprendo nuove opportunità per tutti gli attori del sistema salute – spiega Antonio Messina, a capo del business biofarmaceutico di Merck in Italia -. Oggi una realtà come la nostra, che si pone l’obiettivo di rispondere con soluzioni innovative ai bisogni dei suoi interlocutori, siano essi medici o pazienti, non può dedicarsi solo ed unicamente alla ricerca e sviluppo di nuovi farmaci sempre più efficaci. Dobbiamo essere un “Healthcare provider” a 360 gradi, capace di adottare la tecnologia per rispondere alle esigenze terapeutiche ancora insoddisfatte. Per fare ciò, nessuna azienda, qualunque sia la sua dimensione, può avere la presunzione di riuscire a fare tutto da sola, contando unicamente sulle idee e sulle conoscenze al suo interno. E’ per questo che abbiamo lanciato questa sfida alla creatività di giovani talenti, certi che la loro visione e le loro intuizioni potranno aiutarci a creare soluzioni veramente innovative per la salute”.I partecipanti a H-ACK MERCK FOR HEALTH, suddivisi in team eterogenei tra sviluppatori, designer e marketing specialist, saranno chiamati a sviluppare un progetto a scelta fra uno dei seguenti ambiti: 
come supportare la relazione medico/paziente; BigData&Analytics; come migliorare l’aderenza alla terapia; idee dall’approccio “disruptive” e innovativo.
Durante la 24 ore non mancheranno momenti di approfondimento e di ispirazione grazie alla partecipazione di importanti ospiti: Carsten Vogt dell’Innovation Center di Merck, Alessandro De Luca, Chief Information Officer di Merck HealthCare, Roberto Ascione, CEO di Healthware International, e Guendalina Graffigna, Professore Associato, Facoltà di Psicologia dell’Università Cattolica del Sacro Cuore di Milano.All’evento parteciperà inoltre il top management di Merck Ventures, la società globale di venture capital di Merck, il cui compito è di investire in tecnologie innovative e prodotti con il potenziale per avere un impatto significativo nelle principali aree di business di Merck.Grazie alla collaborazione con l’Innovation Center Merck di Darmstadt, poi, il secondo classificato avrà la possibilità di partecipare per quattro mesi al programma di accelerazione di Merck che prevede: accesso all’Innovation Center ed ai suoi spazi di co-working; possibilità di networking con gli stakeholder Merck basati a Darmstadt; accesso alla piattaforma online “Innovator Academy”.
Inoltre i classificati dalla terza alla quinta posizione potranno accedere direttamente alla selezione finale del prossimo programma di accelerazione di Merck.Accederanno direttamente alla presentazione finale, con la possibilità di essere tra i team premiati, i 5 progetti selezionati durante gli appuntamenti Merck for Health organizzati a Milano, Bari e Roma nei mesi scorsi, realizzati per approfondire i principali scenari di innovazione in ambito salute e promuovere l’incontro tra l’azienda, il digitale e i giovani creativi. Per iscrizioni: http://h-ack.com/healthbymerck

Posted in Roma/about Rome, Spazio aperto/open space | Contrassegnato da tag: , , | Leave a Comment »

Addressing the migration healthcare challenge

Posted by fidest press agency su giovedì, 21 aprile 2016

migrationMany people have put their health at risk travelling to and through the EU because of upheavals in their home countries that have led to the current migration situation. The infections, diseases migrants have caught alongside the psychological damage they have suffered pose challenges for healthcare systems of frontline countries. This has been thrown under the spotlight in the latest FRA summary report of migration-related fundamental rights concerns drawing on data from the nine Member States most affected by the migration flows. While the right to health is a basic right, FRA found differences in the provision of healthcare across the nine Member States covered by its monthly data collection. For example:
In most Member States, health screenings target asylum seekers; in a few Member States they target all newly-arrived migrants. In some Member States, the health screening only identifies cases of communicable diseases; in others it also identifies individual health needs and people belonging to vulnerable groups.
No Member State collects systematic data on the health of newly-arrived migrants and asylum seekers and on their use of the healthcare system. Most Member States do not have specific mechanisms in place to prevent violence against women in reception or detention centres. Under EU Directives, Member States should provide necessary healthcare which includes, at least, emergency care and essential treatment of illnesses. According to the data collected, a number of healthcare challenges in reception centres were identified. These included: limited entitlements to healthcare; practical/administrative barriers; cost of treatment and/or medicines; limited availability of healthcare professionals; poor sanitation conditions and overcrowded spaces; lack of interpreters.
The data also revealed that the main health issues are skin infections, respiratory diseases, colds and psychological issues. A few countries reported specific health problems affecting migrant children. Maternity care was also an issue in some Member States.
FRA has been collecting data about the fundamental rights situation of people arriving in Member States that have been particularly affected by large migration movements, following a request from the European Commission. The countries covered are Austria, Bulgaria, Croatia, Germany, Greece, Hungary, Italy, Slovenia and Sweden.FRA published weekly overviews from September to November 2015 which became monthly from January 2016. Each overview covers a variety of different issues, including:
initial registration and asylum applications, with particular attention to the situation of vulnerable people;
criminal proceedings initiated for offences related to irregular border crossing;
child protection;
reception conditions for new arrivals, focusing on the situation of children and other vulnerable people;
access to healthcare;
public response such as rallies of support, humanitarian assistance or voluntary work;
racist incidents such as demonstrations, online hate speech or hate crime.
While this month has a special section looking specifically at healthcare, last month there was a section focusing on children. Next month, FRA will highlight human trafficking and smuggling.

Posted in Estero/world news, Welfare/ Environment | Contrassegnato da tag: , , | Leave a Comment »

Biotecnologie ed Innovazione in Medicina

Posted by fidest press agency su venerdì, 9 ottobre 2015

merck seronoSocial network, communities, blog, forum: con l’avvento del Web 2.0 cosa è cambiato per i professionisti dell’informazione chiamati ad informare in maniera corretta e referenziata sui temi della salute? E’ possibile realizzare una comunicazione efficace in ambito healthcare senza ascoltare la Rete e confrontarsi con essa? Per discutere di questi e altri aspetti,
., affiliata italiana di Merck, ha riunito oggi a Roma esponenti del mondo della comunicazione, dell’Healthcare e del biotech in occasione dell’’incontro “Biotecnologie ed Innovazione in Medicina sul Web 2.0. Fonti di informazione, fruitori, linguaggi”.
“Le applicazioni del Web 2.0 sono diventate uno strumento sempre più importante per la discussione ed il confronto sui temi legati alla salute – ha spiegato Antonio Tosco, Direttore Health Outcomes & Market Access di Merck Serono S.p.A.: i nuovi media altamente interattivi hanno cambiato i modelli di fruitore, le aspettative dei fruitori stessi e, ovviamente, anche i linguaggi. Di fronte a questi stravolgimenti, come si deve comportare il giornalista che si occupa di temi Healthcare? L’informazione giornalistica sulla salute risponde ancora ai bisogni dei suoi fruitori? E come ci si può adeguare a questi nuovi bisogni senza tradire la propria “mission” professionale e continuando a garantire un’informazione corretta? Nell’incontro di oggi abbiamo voluto provare a rispondere a questi interrogativi, con l’aiuto di esperti e studiosi del Web 2.0”.
Questi gli spunti di riflessione emersi dal dibattito
1. Linguaggio dei Social vs corretta informazione: perché entrano in conflitto
“Sul web, così come sui social – ha dichiarato Federico Mello, Giornalista del programma televisivo Ballarò e blogger Huffington Post – tutto tende a funzionare seguendo le dinamiche del feedback. On line ogni cosa è infatti misurabile: le visite, i ‘mi piace’, i retweet, i commenti, i follower, le condivisioni, i preferiti. Inoltre, molti mattoni di comunicazione (che siano un post o un tweet), mostrano in maniera plateale al navigatore il loro grado di popolarità, facendo scattare così il tipico ‘effetto BandWagon’, ovvero “Guardo quel video perché lo stanno guardando tutti”. Se a queste constatazioni – ha proseguito il Dottor Mello – aggiungiamo il fatto che ogni testata digitale ha numerosi strumenti (analisi dei flussi di traffico, risposta dei social network, link in entrata, ecc…) per poter analizzare i feedback dei suoi contenuti, ecco che il rischio di compromettere una corretta informazione è dietro l’angolo. All’obiettivo di informare, infatti, si sostituisce quello di raccogliere visite. A tutt’oggi comunque una informazione al contempo efficace, completa e ‘virale’ è possibile, ma risulta impossibile – ha concluso Mello – realizzare un buon servizio agli utenti se l’obiettivo di qualsiasi impresa editoriale rimane la caccia ai click. Questo naturalmente vale ancora di più per alcuni campi delicati dell’informazione, come quella medico-scientifica.”
2. Tecnologie digitali: come è cambiato il modo di raccontare e condividere l’esperienza della malattia. “Oggi le conversazioni online sulla salute, la malattia e le terapie – ha spiegato Cristina Cenci, Senior Consultant Eikon Strategic e curatrice del Blog Digital Health, Nòva Il Sole24Ore – consentono di condividere con altri ‘pazienti come me’ le paure, le aspettative, gli effetti dei farmaci. Questo cambia radicalmente la percezione e il percorso della malattia. Nel momento della cura, le discussioni online contribuiscono all’aderenza terapeutica ma anche a determinare effetti placebo e nocebo dei farmaci. Quando la malattia è cronica, le comunità online offrono quel supporto che mai nessun sistema sanitario o network di caregiver è mai riuscito ad offrire prima. La sfida allora per la comunicazione e i media – ha concluso la Dott.ssa Cenci – è ascoltare il discorso sociale online e acquisire la consapevolezza che il racconto di malattia non può essere scientificamente avalutativo, ma deve avere senso e significato dal punto di vista del soggetto. Serve empatia narrativa, bisogna trovare il giusto linguaggio e le metafore adeguate per comunicare questi temi partendo dall’ascolto di quello che si condivide in rete, un osservatorio fondamentale delle esigenze e delle rappresentazioni collettive.”
3. Gli italiani e l’informazione sulla salute in Rete: usi e consumi. “I trend degli ultimi 10 anni mostrano una crescente sensibilità al tema salute – ha sottolineato Stefania Fregosi, Direttore delle ricerche quantitative Dipartimento Salute GfK Eurisko. – Il paziente diventa sempre più attento, sensibile, competente, con una conseguente ‘espansione’ delle pratiche di salute: aumentano infatti i comportamenti ‘preventivi’, cresce la popolazione attenta. In questo nuovo contesto la ricerca di informazioni appare centrale e sembra ridefinire la tradizionale relazione medico-paziente (medico informato, paziente passivo). Internet diventa un luogo cruciale per cercare e condividere informazioni ed esperienze. Come noto, cresce esponenzialmente negli ultimi 10 anni la quota degli internauti (dall’11 al 68% degli Italiani maggiorenni) ed aumenta in modo consistente la percentuale di chi si informa sulla salute nel web: circa l’85% degli utenti, infatti, ha cercato informazioni sulla salute sui siti Internet e quasi il 30% ha partecipato a discussioni di salute su blog, forum, chat.1 In questa prospettiva – ha spiegato la Dott.ssa Fregosi – appare cruciale per chi opera nel settore della salute cogliere la sfida e far fronte ai bisogni del «cittadino-paziente internauta». Si tratta di una sfida a due livelli: da un lato riguarda i servizi al cittadino (Come dare risposta ai bisogni di competenza e confronto? Quali servizi, quali strumenti offrire al cittadino? Come assicurare un’informazione garantita nel web?), dall’altro riguarda la relazione medico-paziente, ovvero come «ri-definire» un nuovo tipo di relazione che legittimi e valorizzi il bisogno di protagonismo e consapevolezza del paziente nella gestione della propria salute (così importante nel determinare il successo della cura), senza mettere in difficoltà il ruolo del medico a cui il paziente vuole e continua ad affidarsi.”
4. Comunicare il valore del biotech: l’esperienza di Farmindustria. “Le biotecnologie sono oggi la frontiera dell’innovazione in Italia – ha affermato Agostino Carloni, Direttore Comunicazione, Stampa e Studi Farmindustria. Se ci soffermiamo sul solo settore Salute, abbiamo 3.900 addetti in R&S, 199 aziende del farmaco biotech, 88% degli investimenti in R&S sul totale effettuati dall’industria del farmaco, 145 farmaci biotecnologici oggi disponibili nel mondo e 303 progetti in fase di ricerca e sviluppo. Grazie alla ricerca farmaceutica sempre più biotech – prosegue Carloni – sono migliorate molte terapie esistenti e individuati nuovi trattamenti per malattie finora ritenute senza cura.
Per questo Farmindustria, nell’ultimo anno, ha avviato una serie di eventi per una maggiore informazione sulla realtà biotech. Esempi di questo impegno sono diversi progetti che hanno i giovani come target di riferimento come Geni a bordo: la scienza viaggia in Camper, format di divulgazione itinerante realizzata negli istituti superiori italiani, e la collaborazione con Wired attraverso video, infografica e social network.”

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »